registration
Schientific Committee
Chairs and Faculty
Program
Accreditation
Abstracts
Young Investigators
Accommodations
Support or Exhibit
Contact Us
Home Page

Program

Thursday, January 12, 2012
4:00 – 7:00 PM Registration
5:30 – 7:00 PM Welcome Reception
Friday, January 13, 2012
7:30 AM Registration/Continental Breakfast
8:25 Welcome and Opening Remarks, Antonino Catanzaro, MD and Charles L. Daley, MD
8:30 The New Understanding of the Dynamics of TB Infection, Clifton E. Barry, III, PhD
9:00 Discussion
9:10 What IGRAs Have Allowed Us to Understand About TB, David Lewinsohn, MD, PhD
9:40 Discussion
9:50 Commentary, Michael D. Iseman, MD
10:10 Discussion
10:20 Break
10:40 What Does the Experience with Immune Modifiers Tell Us About the Mechanism and Risk of Progression to TB Disease, Robert S. Wallis, MD, FIDSA
11:10 Discussion
11:20 Commentary, Jerold J. Ellner, MD
11:40 Discussion
12:00 PM Luncheon
1:30 Do IGRAs Identify Persons Who Are Likely Not to Progress to Active TB, Albert Nienhaus, MD, PhD
2:00 Discussion
2:10 How Well Do IGRAs Perform the Identification of Persons Who Are Likely to Progress to Active TB, Pranab Haldar, MD, MRCP
2:40 Discussion
2:50 Break
3:10 Predictive Value of IGRAs for Progression to Active Tuberculosis in HIV 1 Infected Women, S. Jonnalagadda
3:20 Discussion
3:25 Predictive Value of IGRAs for Progression to Active Tuberculosis in TB Contacts in Singapore, C. Chee
3:35 Discussion
3:40 Predictive Value of IGRAs for Progression to Active Tuberculosis in Children: Results of a Longitudinal Study in Germany Using IGRAs, Stefanie Castell, MD, MSc
3:55 Discussion
4:00 Commentary, Ibrahim Abubakar, MD, PhD
4:15 Discussion
4:30 Adjourn
5:30 Hawaiian Luau
Saturday, January 14, 2012
7:30 AM Continental Breakfast
8:25 Opening Remarks, Charles L. Daley, MD
8:30 Use of IGRAs In the Face of Other Co Morbidities, Luca Richeldi, MD, PhD
9:00 Discussion
9:10 Repeated Quantiferon TB Gold in Tube Tests in Routine Clinical Practice: AFive Years Experience, S. Cerr
9:20 Discussion
9:25 Use of IGRAs in the Face of HIV Immune Modifiers, Pernille Ravn, MD, PhD
9:55 Discussion
10:05 Screening HIV Infected Patients with IGRAs for LTBI, K. Sakashita
10:15 Discussion
10:20 Break
10:40 Serial Testing with IGRAs in High Risk Populations, R. Garfein
10:50 Discussion
10:55 Use of IGRAs in the Face of Immune Modifiers, Stephan Gadola, MD, PhD
11:25 Discussion
11:35 What is the Effect on the IGRA Response By Prednisolone, Tobacco or Inflammatory Bowel Disease? A. Werlinrud
11:45 Commentary, Neil Schluger, MD
12:05 PM Discussion
12:15 Luncheon
1:30 IGRA Testing of HCW, Charles L. Daley, MD
2:00 Discussion
2:10 Active TB in Portuguese HCW, a Descriptive Study, José Castela Torres da Costa
2:20 Discussion
2:25 IGRAs and Missed Opportunities to Prevent Active Tuberculosis in Healthcare Workers with Positive Tuberculin Skin Tests Attributed to Bacille Calmette Guerin (BCG) Vaccination, J. Katsolis
2:35 Discussion
2:40 Cost Effectivness and Operating Characteristics of Using Igras in US Healthcare Workers, W. Thanassi
2:50 Discussion
2:55 Commentary, Renee Ridzon, MD
3:15 Discussion
3:25 Break
3:45 Interpretation of IGRA Results, Edward A. Graviss, PhD, MPH
4:15 Discussion
4:25 Within Subject Variability of the Quantiferon TB Gold in Tube Assay in a Large Cohort of Low Risk Subjects, J. Metcalfe
4:35 Discussion
4:40 A Data Based Algorithm for the Clinical Management of Persons with Fluctuations in Serial IGRA Tests to Detect LTBI, D. Marder
4:50 Discussion
5:00 Commentary, Matthew J. Binnicker, PhD
5:20 Discussion
5:30 Poster Session
6:30 PM Adjourn
Sunday, January 15, 2012
7:30 AM Continental Breakfast
8:25 Opening Remarks, Charles L. Daley, MD
8:30 Dried Plasma Spots in the Diagnosis of TB Infection: IP-10 Release Assay on Filter Paper, M. Ruhwald
8:40 Discussion
8:45 Pilot Study of Latent Tuberculosis Infection with an Enhanced Elispot Interferon Gamma Release Assay, P. Escalant
8:55 Discussion
9:00 Cost Effectiveness of IGRAs Versus Chest X Ray for Tuberculosis Screening, A. Kowada
9:10 Discussion
9:15 Prevalence of LBTI in the General Public in Mazovia and HCW in Poland Using Igras, U. Demkow
9:25 Discussion
9:30 Screening of HCW and Immigrants with IGRA and TST in Mexico L. Todd, L. Machado, A. Diaz
9:40 Discussion
9:45 Commentary, Toru Mori, MD, PhD
10:05 Discussion
10:15 Break
10:30 The Use of IGRAs in Children: View From the Laboratory, Beate Hyme, FRCPCH, MD, PhD
11:00 Discussion
11:30 The Use of IGRAs in Children: View from the Clinic, Jeffrey Starke, MD
12:00 PM Discussion
12:10 Luncheon
1:30 What Would it Take to Eliminate Tuberculosis by 2050, Laith J. Abu-Raddad, Phd
2:00 Eliminating TB by 2050, Mario Raviglione, MD
2:30 Discussion
2:40 Global Applications, Richard O'Brien, MD
3:10 Discussion
3:20 Break
3:40 How Does the Concept of Diagnosing and Treating LTBI Fit Into TB Control in Low, Medium and High Burdon Countries, Edward Nardell, MD
4:10 Discussion
4:20 Closing Comments, Antonino Catanzaro, MD
4:30 PM Adjourn

 


ucsd

UC San Diego School of Medicine
Continuing Medical Education
2251 San Diego Ave., A-160
San Diego, CA 92110

Phone: (619) 543-7602 • Toll-Free: (888) 229-OCME (6263) • Fax: (619) 543-7610
E-mail: ocme@ucsd.edu • Website: cme.ucsd.edu


For technical comments or questions, contact the webmaster.
Copyright 2011, University of California, San Diego. All rights reserved.